Sleep · 7 min read

Melatonin: Sleep Hormone or Sleep Crutch?

Published June 2025·5 sources reviewed

The Dose Problem Nobody Talks About

Melatonin is the most purchased sleep supplement in the United States, with annual sales exceeding $800 million and growing. It occupies a culturally comfortable position: a hormone your body already produces, available without prescription, associated with the natural sleep-wake cycle rather than the stigmatized territory of sleeping pills. The marketing is soothing. The science is more complicated — and the doses sold in most commercial products have almost no relationship to the doses that research supports.

The pineal gland secretes melatonin in response to darkness, typically beginning to rise around 9–10pm and peaking between 2–4am. It does not cause sleep directly — it signals to the body that it is nighttime, facilitating the transition to sleep. The endogenous nighttime surge produces blood melatonin levels of roughly 0.1 to 0.3 nanograms per milliliter. A standard 5mg supplement tablet produces blood levels approximately 10 to 100 times higher than this physiological range. A 10mg gummy — now commonly marketed and widely sold — produces levels that bear essentially no relationship to normal human melatonin biology.

The clinical evidence for melatonin is strongest in two specific applications: jet lag (where it helps reset circadian timing when crossing time zones) and delayed sleep phase syndrome (where the circadian clock is systematically shifted later than desired). For these applications, the effective doses in research are typically 0.5 to 1mg — not 5mg or 10mg. For general insomnia in otherwise healthy adults, the evidence is considerably weaker. A 2022 meta-analysis in JAMA found that melatonin reduced sleep onset latency by an average of 1.8 minutes compared to placebo — a statistically significant but clinically marginal result.

"Most people are taking doses ten to fifty times higher than what produces any documented benefit. Melatonin at 0.5mg works for circadian shifting. Melatonin at 10mg is pharmacological territory — we genuinely don't know what chronic high-dose melatonin does to the endocrine system over years of use."
— Dr. Charles Czeisler, Director of the Division of Sleep Medicine, Harvard Medical School

The children's melatonin market warrants particular attention. Gummy formulations in doses of 1–5mg have become common for children's sleep, despite the near-total absence of long-term safety data for melatonin in developing endocrine systems. Melatonin receptors are present throughout the body — not just in sleep-regulating brain regions — and their role in pubertal timing, reproductive development, and immune function in children is not well characterized. The American Academy of Sleep Medicine does not recommend melatonin for children with chronic insomnia, citing insufficient evidence.

The Labeling Problem

A 2023 study published in JAMA tested 25 commercially available melatonin supplements and found that the actual melatonin content deviated from the labeled dose by up to 478%. One product labeled as 1.5mg contained 9mg. Another contained serotonin — an unlabeled active compound — that was not disclosed on the packaging.

Because melatonin is classified as a dietary supplement rather than a drug in the United States, manufacturers are not required to demonstrate potency, purity, or efficacy before sale. The FDA does not review supplements before they reach the market. This regulatory gap means consumers have essentially no reliable way to verify that a melatonin product contains what the label states.

In contrast, melatonin is classified as a prescription medication in the United Kingdom, Germany, and Australia — requiring physician authorization and subject to pharmaceutical manufacturing standards. The same molecule is sold as candy in US convenience stores.

FactoraHealth Comparison Table

The Claim	What the Science Says
"Helps you fall asleep faster"	Meta-analysis: ~1.8 min faster sleep onset vs placebo; effect is real but clinically modest for most users
"5–10mg is a safe dose"	Research supports 0.5–1mg for circadian effects; commercial doses 10–100x exceed physiological levels
"Safe for children"	Long-term safety data in children is essentially absent; endocrine effects in developing systems are unknown
"Label dose is accurate"	JAMA 2023: actual content deviated up to 478% from label; some products contained unlabeled active compounds

So What Should We Make of This?

Melatonin has legitimate uses — jet lag, circadian rhythm adjustment, and short-term sleep onset support. The effective doses for these purposes are dramatically lower than what is sold commercially. If you use melatonin, 0.5mg taken 30–60 minutes before target bedtime is supported by evidence. The 5mg and 10mg products widely available are pharmacological doses with no corresponding pharmacological evidence of benefit.

The more important question is what the sleep problem actually is. Melatonin does not treat the underlying causes of chronic insomnia — anxiety, poor sleep hygiene, irregular schedules, screen exposure, caffeine timing. Cognitive behavioral therapy for insomnia (CBT-I) has the strongest evidence base for chronic sleep problems and produces durable improvements without the unresolved questions around long-term supplementation.

If you are giving melatonin to children: the short-term safety data is reassuring, but long-term effects on developing endocrine systems are genuinely unknown. This is not a reason for panic, but it is a reason to use the lowest effective dose for the shortest necessary duration — and to address the behavioral and environmental causes of sleep difficulties first.